Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation

This case, IPR2023-00608, involves a challenge by Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation (collectively, "Novartis") against claims 5 and 6 of U.S. Patent No. 9,051,542, owned by Genzyme Corporation. Novartis, a global pharmaceutical giant, through its subsidiary Novartis Gene Therapies, specializes in developing gene therapies for rare neurological genetic disorders, most notably the high-profile drug Zolgensma. Genzyme, now a subsidiary of Sanofi, is a biotechnology company focused on developing treatments for rare diseases, particularly enzyme therapies. The dispute centers on the '542 patent, which broadly covers compositions and methods for preventing aggregation of adeno-associated virus (AAV) virions in high-concentration solutions, crucial for the stability and efficacy of gene therapy products.

The procedural posture is an Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB), a specialized administrative court within the U.S. Patent and Trademark Office. Novartis challenged claims 5 and 6 of the '542 patent (claims 1 and 2 having been disclaimed by Genzyme). The PTAB denied Novartis's petition on August 30, 2023, concluding that the Petitioner had not demonstrated a reasonable likelihood of prevailing with respect to proving the challenged claims unpatentable. The PTAB provides an alternative to federal district court litigation for challenging patent validity, often favored for its technical expertise and potentially faster, less costly process.

This IPR is notable as it is intricately linked to broader patent infringement litigation. Genzyme Corporation and Aventis Inc. previously sued Novartis Gene Therapies and Novartis Pharmaceuticals Corporation in the District of Delaware, alleging infringement of several patents, including the '542 patent, all related to recombinant adeno-associated virus (AAV) vector technology underpinning Novartis's blockbuster gene therapy, Zolgensma. Zolgensma (onasemnogene abeparvovec-xioi) is a one-time gene therapy for spinal muscular atrophy (SMA) and is recognized as one of the world's most expensive drugs. The district court litigation ultimately settled, with all asserted claims dismissed with prejudice after claim construction, findings of non-infringement on some patents, and the institution of multiple IPRs, highlighting the strategic use of IPRs in high-stakes pharmaceutical patent disputes. Novartis had filed two separate petitions (IPR2023-00608 and IPR2023-00609) against the '542 patent, a practice the patent owner characterized as potentially burdensome to the Board.

Key Legal Developments and Outcome in Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation Litigation

This case involved parallel patent infringement litigation in the District of Delaware and Inter Partes Review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) concerning US Patent 9,051,542 and other related patents.

Patent Infringement Litigation (Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al., D. Del. Case No. 1:21-cv-01736)

1. Filing & Initial Pleadings (2021-12-10 - 2022-02-23):
Genzyme Corporation and Aventis Inc. (Plaintiffs) filed a patent infringement lawsuit against Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation, and Novartis AG (Defendants) in the District of Delaware on December 10, 2021. The initial complaint alleged infringement of five patents related to recombinant adeno-associated virus (rAAV) vectors used in Novartis's gene therapy drug, Zolgensma®. An amended complaint, filed on February 23, 2022, added US Patent 9,051,542 to the asserted patents, bringing the total to six patents. The asserted patents covered AAV gene therapy technology for Zolgensma.

2. Pre-trial Motions & Claim Construction (2023-08-18):
The case proceeded to claim construction. On August 18, 2023, Judge Richard G. Andrews issued a Memorandum Opinion providing claim construction for multiple terms across the asserted patents, including US Patent 9,051,542. According to counsel for Novartis, this claim construction led to the invalidation of four patents and a finding of non-literal infringement for five patents.

3. Discovery Milestones:
While specific discovery milestones for the district court case are not fully detailed in the provided information, IPR filings from the parallel PTAB proceedings indicated that fact discovery was closing and expert reports regarding invalidity were being served around the time of the IPR institution decisions, suggesting active discovery in the district court case.

4. Trial Events & Outcome (2024-02-14):
A five-day jury trial on US Patent 9,051,542 was scheduled for March 25, 2024. However, the parties ultimately reached a settlement. On February 14, 2024, the district court case was dismissed with prejudice via a joint stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The dismissal with prejudice signifies a final adjudication on the merits, preventing Genzyme from reasserting the same claims against Novartis. Each party agreed to bear its own legal fees and costs. MediciNova, which held an assignment agreement with Genzyme, later announced on November 11, 2024, that it was notified by Sanofi (Genzyme's parent company) of the settlement and that MediciNova was entitled to monetary damages from it.

Parallel PTAB IPR Proceedings

1. IPR Filing (2023-02-22):
Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation (Petitioners) filed two Inter Partes Review petitions, IPR2023-00608 and IPR2023-00609, on February 22, 2023, challenging claims of US Patent 9,051,542. Specifically, IPR2023-00608 challenged claims 1, 2, 5, and 6 of the '542 patent.

2. Patent Owner's Response & Disclaimer of Claims (2023-06-16 - 2023-08-22):
Prior to the PTAB's institution decision for both IPR2023-00608 and IPR2023-00609, Genzyme (Patent Owner) disclaimed claims 1 and 2 of US Patent 9,051,542. This disclaimer was effective on June 16, 2023, and filed with the USPTO on August 22, 2023. The PTAB noted Novartis's filing of two petitions challenging only four claims, raising concerns about placing a substantial and unnecessary burden on the Board.

3. IPR Outcome (2023-08-30):
On August 30, 2023, the Patent Trial and Appeal Board denied institution of IPR2023-00608. The petition was denied because the Patent Owner had disclaimed claims 1 and 2 prior to the institution decision, and the Petitioner did not demonstrate a reasonable likelihood of prevailing with respect to the remaining challenged claims (claims 5 and 6). Similarly, IPR2023-00609 was also not instituted on the merits following the disclaimer of claims 1 and 2.

4. Effect on Litigation:
The IPR proceedings, particularly the disclaimer of claims 1 and 2 of US Patent 9,051,542 by Genzyme and the non-institution of the IPRs, likely contributed to the overall strategic landscape that led to the settlement of the district court litigation. According to Novartis's counsel, the comprehensive settlement followed the invalidation of four patents during claim construction, findings of non-literal infringement for five patents, and the institution of multiple IPRs (though specific IPRs on the '542 patent were not instituted, others related to different patents in the broader dispute were initiated or terminated by settlement).

Other Parallel IPRs:
Separately, Novartis also challenged US Patent 10,429,288 in IPR2023-01044 and IPR2023-01045. These IPRs, associated with another district court case (1:23-cv-00554-RGA), were terminated on March 4, 2024, based on a confidential settlement agreement between the parties, further indicating a broader resolution of disputes between Novartis and Genzyme.

In IPR2023-00608, Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation (the Petitioners) were represented by attorneys from Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.

The following counsel were identified as representing the plaintiff(s):

• John D. Livingstone

  • Role: Counsel
  • Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. The specific office location for Mr. Livingstone in relation to this case is not explicitly stated in the provided search results, but Finnegan has offices in various locations, including Washington, D.C., Boston, and Atlanta, among others.
  • Relevant Experience Note: Mr. Livingstone is listed as counsel for Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation in this IPR and was also involved in receiving service for Novartis in the related IPR2023-00609. Finnegan successfully defended Novartis against Genzyme's multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis' gene therapy Zolgensma®, which ultimately settled.

• Amanda K. Murphy, Ph.D.

  • Role: Counsel
  • Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. The specific office location for Dr. Murphy in relation to this case is not explicitly stated in the provided search results, but she is listed as a related professional in Finnegan's successful defense of Novartis against Genzyme's patent infringement and IPR proceedings.
  • Relevant Experience Note: Dr. Murphy possesses a Ph.D., indicating a strong technical background, and was involved in receiving service for Novartis in IPR2023-00608 and IPR2023-00609. She was part of the Finnegan team that defended Novartis against Genzyme in patent litigation concerning AAV vector technology.

• Yieyie Yang

  • Role: Counsel
  • Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. The specific office location for Ms. Yang in relation to this case is not explicitly stated in the provided search results.
  • Relevant Experience Note: Ms. Yang was listed as receiving service for Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation in IPR2023-00608 and IPR2023-00609.

Here is the counsel of record representing Genzyme Corporation in IPR2023-00608:

• Name: Blaine M. Hackman
• Role: Counsel for Patent Owner
• Firm: Dechert LLP
  • Office Location: Three Bryant Park, 1095 Avenue of the Americas, New York, NY 10036-6797
• Relevant Patent Litigation Experience: Mr. Hackman is identified as counsel for Patent Owner Genzyme Corporation in this IPR and a related IPR (IPR2023-00609) concerning U.S. Patent No. 9,051,542. He has also been involved in other IPR proceedings, such as IPR2025-01195 and IPR2026-00150, representing patent owners.